Posts tagged “Novartis”
The breakthrough $1 billion-plus Novartis cell culture vaccine factory in Holly Springs will be rebranded in October with a new name and logo announced by its new owner, CSL.
GSK malaria vaccine nearer OK; Aerie not giving up on glaucoma treatment; Duke Energy's Greentech award; Novartis soars; CDC's new tech tracks listeria
In the latest wrapup of technology and life science news: GSK's malaria vaccine is closer to approval after clinical trial; Aerie Pharmaceuticals not giving up on glaucoma treatment; Duke Energy wins a Greentech award; Novartis soars in wake of GSK, Eli Lilly deals; CDC uses new tech to track listeria illnesses.
Drug giants GlaxoSmithKline and Novartis say they have formally closed on a deal valued at more than $21 billion to changes each company in dramatic fashion. Plus, they are moving ahead with a joint venture focusing on consumer healthcare.
Reddit, Google crack down on nude photos; GSK-Novartis deal nears close; Apple loses $539.M dispute; INC's first results; honor for Quintiles
In today's Bulldog wrapup of technology and life science news: Reddit and Google are cracking down on nude photos; GSK says Novartis deal nears close; Apple loses a big patent verdict; INC reports results; an honor for Quintiles.
Drug giant Novartis is selling its $1-billion vaccine production plant in Holly Springs to Australia-based CSL as part of a deal valued at $275 million. Novartis is disposing its entire influenza-related vaccine business through this transaction that was announced Sunday night. Some 550 people work at the Holly Springs facility.
Pharmaceutical maker Novartis on Wednesday celebrated the U.S. Food and Drug Administration's licensing and first shipments of a new flu vaccine that the company says could drastically help with reducing a potential pandemic.
Novartis dedicates $1B vaccine plant with VIP flu shots as NC exec who recruited the firm will watch
It's probably a safe bet that Gov. Pat McCrory has already received his flu shot for the 2014-5 season, but he and other VIPs can line up for vaccinations today as Novartis formally dedicates production at its mammoth $1 billion plant in Holly Springs. But there's also an interesting back story to the event: The N.C. Biotechnology Center exec who helped recruit Novartis to N.C. way back in 2006.
Yahoo earnings fall; N.C. Solar Center's new name; Novartis-Google 'Glass' contacts; Cree expands; Sling's new devices
In today's Bulldog wrapup of technology and life science news: Yahoo takes a hit; N.C. Solar Center gets a new name; Novartis teams with Google for "Glass" contacts; Cree adds space; Sling's new devices.
In the third part of a series offering an overview of North Carolina's global prominence as a home for life science companies, the N.C. Biotechnology Center's Jim Shamp provides an overview of vaccine development.
The revolution has nothing to do with its proximity to the July 4 Independence Day holiday. Rather, it's in the way Flucelvax from Novartis is made at the plant. It's the first flu vaccine produced without antibiotics and preservatives, using a unique biological "soup" called cell culture.
Plans for pharmaceutical giants Novartis, GlaxoSmithKline and Eli Lilly to swap business lines may have shaken up the stock market Tuesday, but work at a Novartis flu vaccine plant in Holly Springs hummed along, and local officials said they expect it to remain that way.
GSK's top executive Andrew Witty says the multiple deals announced early Tuesday with Novartis promise to deliver "broadly sustainable sourced sales growth and improve long-term earnings."
Two drug giants with major operations in the Triangle, Novartis and GlaxoSmithKline, are swapping businesses in two major deals. Meanwhile, Novartis plans to sell its huge Holly Springs plant in a separate deal and also strikes an agreement to sell its animal health business to Eli Lilly. No layoffs are planned, Novartis says.
Drug giants Novartis and GlaxoSmithKline each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the Novartis presentation.
Drug giants GlaxoSmithKline and Novartis each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the GSK presentation.
- GSK pharma chief to quit after losing out on CEO job
- US suit: Oracle pays white male workers more, favors Asian workers in recruiting
- GOP governors who turned down Medicaid money have hands out
- Theresa May seeks to convince business of a 'global Britain'
- Trump plans for Scottish resort spark new conflicts concern